Patsatsi Aikaterini, Marinovic Branka, Murrell Dedee
Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Greece.
Department of Dermatology, School of Medicine, University of Zagreb, Croatia.
Int J Womens Dermatol. 2019 Jan 24;5(3):166-170. doi: 10.1016/j.ijwd.2019.01.003. eCollection 2019 Jul.
Autoimmune bullous diseases during pregnancy pose a therapeutic challenge for medical dermatologists. There are main concerns with regard to the regimen, dose, route of administration, and potential harm to the fetus. Many therapeutic options may be safe during pregnancy despite official classifications. Furthermore, there are always questions regarding management during the lactation period. Additionally, issues exist about male and female fertility and the time of discontinuation of certain medications before conception. In this article, we present an overview of the literature based on answers to these issues to solve common and uncommon management problems that arise about a spectrum of autoimmune bullous diseases before conception, as well as during pregnancy and the lactation period.
妊娠期自身免疫性大疱性疾病给皮肤科医生带来了治疗挑战。在治疗方案、剂量、给药途径以及对胎儿的潜在危害方面存在主要担忧。尽管有官方分类，但许多治疗选择在妊娠期可能是安全的。此外，哺乳期的管理也总是存在问题。另外，关于男性和女性的生育能力以及受孕前停用某些药物的时间也存在问题。在本文中，我们基于对这些问题的回答对文献进行综述，以解决在受孕前、妊娠期以及哺乳期一系列自身免疫性大疱性疾病出现的常见和罕见管理问题。
